AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03593759
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral, subcutaneous, or intramuscular methotrexate
Trial: NCT00590863
Drug: SSRI + placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take escitalopram (10 - 20 mg/day)+ placebo (1 to 3 pills per day). Medications taken orally. Participants will take escitalopram plus placebo for up to 28 weeks. Dosages were adjusted as need at each clinic visit.
Trial: NCT04214301
Drug: BLI800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BLI800 Bowel Preparation
Trial: NCT03374540
Drug: Vitamin K antagonist (VKA)
RxNorm normalized name: Vitamin K antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individually adjusted dose
Trial: NCT04209465
Drug: BDTX-189
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a daily, oral dose of BDTX-189 as part of a 3 week cycle.
Trial: NCT01683695
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered as subcutaneous injections in the anterior abdomen of the subjects.
Trial: NCT00828763
Drug: [14c}-GSK1349572
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-Integrase inhibitor labelled with a carbon 14 marker
Trial: NCT00300313
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-2 capsules
Trial: NCT00665743
Drug: naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: naproxen 500 mg
Trial: NCT02091245
Drug: KPT-330
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01443702
Drug: Lapis Judaicus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g capsule per day.
Trial: NCT01443702
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g capsule per day.
Trial: NCT00391027
Drug: Inhaled Human Insulin (Exubera®)
RxNorm normalized name: insulin, regular, human Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will be randomized inhaled insulin while remaining on pre-study oral hypoglycemic agents.
Trial: NCT00577824
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, volume equivalent to 5mcg or 10mcg exenatide, twice a day
Trial: NCT01493973
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02954393
Drug: Placebos active phase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin and metronidazole placebos thrice a day for 14 days in the active phase (beginning with the first SRP session).
Trial: NCT02954393
Drug: Placebos healing phase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin and metronidazole placebos thrice a day for 14 days in the healing phase (3 months after active phase).
Trial: NCT02712528
Drug: remifentanil-based
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02712528
Drug: sevoflurane-sufentanil balanced
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01890837
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 2 weeks.
Trial: NCT01480310
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: may receive up to 3 subcutaneous doses of placebo
Trial: NCT03529019
Drug: Ensure Surgery Immunonutrition Shake
RxNorm normalized name: Ensure Surgery Immunonutrition Shake (Vanilla)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An FDA approved nutritional supplement. Prepackaged product designed to be administered one week prior to and one week post surgical procedures.
Trial: NCT00752687
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, or powder drug substance from the capsule mixed in an alternative vehicle. For additional information refer to Arm Description.
Trial: NCT03327116
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral, 15 mg per week, 24 weeks
Trial: NCT01744353
Drug: Dose level 2/MTD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abraxane 150 mg/m2 day 1, Oxaliplatin 85 mg/m2 day 1, leuocovorin 400 mg/m2 day 1, F-FU infusion 1200 mg/m2 day x 2 days IV infusion
Trial: NCT03800433
Drug: Trental 400 MG Extended Release Oral Tablet
RxNorm normalized name: Trental 400 MG Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablets
Trial: NCT03779815
Drug: [18F]Florbetaben
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Drug: \[18F\]Florbetaben~* \[18F\]Florbetaben PET/CT Imaging for detecting amyloidosis in multiple myeloma~* Other name: Neuraceq~* Amount: 300 MBq ± 20% bolus, 10mL intravenously
Trial: NCT00200668
Drug: FDG = fluorodeoxyglucose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00902707
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compare to active Mucinex
Trial: NCT01521663
Drug: IPX159
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03879447
Drug: Herbal medicine
RxNorm normalized name: Herbal medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica) at the physician's discretion.
Trial: NCT00796003
Drug: JNJ-30979754 20 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phase I: JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1. Phase II: JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) cycles until the decitabine was expected to be effective in participants.
Trial: NCT01521663
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00548145
Drug: cholesterol-lowering medicine other than statin(e.g.,Ezetimibe,Colestimide)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: duration: 12 months
Trial: NCT00882960
Drug: intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: An IV will be established and used to deliver Fentanyl at 50 micrograms to patients who meet pre-hospital protocol for pain management. Examples of this may be burn patients, fractures, trauma.
Trial: NCT00882960
Drug: intra-nasal fentanyl
RxNorm normalized name: fentanyl Nasal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a mucosal atomization device will be used to deliver 50 mcg of Fentanyl to patients who have been identified at requiring pre-hospital pain management
Trial: NCT04254601
Drug: topical erythromycin cream 2% (Akne-Mycin- Egypt)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two times per day on the entire face from the beginning to the end of the treatment period .~The face is washed thoroughly with warm water and gentle soap, rinse well, and pat dry, patients were advised to wait 30 minutes before applying the aknemycin. To help keep new pimples from breaking out, the aknemycin was applied to the whole area usually affected by acne, not just to the pimples themselves
Trial: NCT02119663
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg matching placebo tablets to be administered by mouth twice daily (BID)
Trial: NCT01560143
Drug: Tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg IV as a single infusion over 30 minutes
Trial: NCT01268566
Drug: MEDI-575
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI-575 as an IV infusion.
Trial: NCT00928200
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m2/day IV over 15 minutes on day 1
Trial: NCT00928200
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given Intrathecally to all patients who are CNS 1 or 2 at study entry. Dose defined by age. Given on day 15 8mg for age 1-1.99 10 mg for age 2-2.99 12 mg for age 3-8.99 15 mg for age 9 and older
Trial: NCT00511121
Drug: STI571 and PEG INTRON
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00864344
Drug: Zoloft® 100 mg tablets, single dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: B: Active comparator Subjects received Pfizer formulated products under fasting conditions
Trial: NCT04411706
Drug: Sintilimab Combined With Apatinib and Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug: Sintilimab 200mg (3mg/kg for underweight patients) intravenously, every 21 days for a cycle;~Drug: Apatinib,250mg po qd, for continuous medication;~Drug: Capecitabine,1000mg/m2 po bid, d1-d14, every 21 days for a cycle;
Trial: NCT02119663
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 150 mg or 500 mg tablets to be administered by mouth twice daily (BID)
Trial: NCT01324362
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily dosing
Trial: NCT01324362
Drug: FSC 100/50mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily dosing
Trial: NCT01324362
Drug: FSC 250/50mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily dosing
Trial: NCT01324362
Drug: FSC500/50mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily dosing
Trial: NCT00177255
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 825 mg/m2 bid (total daily dose 1650 mg/m2) will be administered orally for 14 days (days 1-14).~Each cycle will consist of 21 days.~Cycle 2 will begin on day 22.
Trial: NCT00352430
Drug: Nitric Oxide/INP Pulse Delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00352430
Drug: Nitric Oxide/INO Pulse Delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01581541
Drug: PU-H71
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PU-H71 is a synthetic HSP90 inhibitor which can bind both open and closed conformations of HSP90. It demonstrates extended tumor retention and client protein degradation, while being rapidly cleared from normal tissues. It has shown complete tumor responses and retained sensitivity to retreatment in vivo.
Trial: NCT00928200
Drug: Triple Intrathecal Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate, Cytarabine and Hydrocortisone given Intrathecally on day 8, 15 and 22 for patients who are CNS 3 at study entry. Doses determined by age.
Trial: NCT03508167
Drug: Dorilax®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets, orally. In case of moderate pain, another 2 tablets could be administered, respecting the interval of 8 hours between the administrations.~Maximum dosage per day: 6 tablets.
Trial: NCT03508167
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets, orally. In case of moderate pain, another 2 tablets could be administered, respecting the interval of 8 hours between the administrations.~Maximum dosage per day: 6 tablets.
Trial: NCT03162419
Drug: Standard Medical Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patients in group A will be given standard medical therapy only as per requirement. Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
Trial: NCT03193710
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remifentanil will be used for analgesia in both groups.
Trial: NCT02237755
Drug: Gonadotropins
RxNorm normalized name: GONADOTROPINS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will be stimulated with a fixed GnRH-antagonist protocol. Ovarian stimulation will be initiated with 450 IU of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH.
Trial: NCT01834352
Drug: Walnut Protein Flour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily ingestion of gradually increasing amounts of walnut protein flour in order to induce desensitization to walnut and an unrelated tree nut.
Trial: NCT02240355
Drug: RO6885247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral solution
Trial: NCT02240355
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral solution
Trial: NCT04239339
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo daily for approximately 3 weeks.
Trial: NCT01605253
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo used in this study looks exactly like eszopiclone but contains no active ingredients.
Trial: NCT01210989
Drug: Phyllanthus urinaria
RxNorm normalized name: Phyllanthus niruri top extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects meeting the inclusion and exclusion criteria will be randomized (2:1) to receive oral Hepaguard 1 g three times daily or placebo of identical appearance. At week 24, subjects receiving active Hepaguard will be randomized (1:1) to continue Hepaguard for another 24 weeks or stop treatment.
Trial: NCT01210989
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects meeting the inclusion and exclusion criteria will be randomized (2:1) to receive oral Hepaguard 1 g three times daily or placebo of identical appearance.
Trial: NCT03537950
Drug: PLC
RxNorm normalized name: Drive Cane Tip Rplc 3/4 Blk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of PLC.
Trial: NCT01764048
Drug: medications following demand protocol
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Please see arm description
Trial: NCT04573608
Drug: Papacarie
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Papacarie was introduced into the cavity using the applicator and left for 40 seconds. A blunt excavator was used to remove the softened dentin. The remaining gel was removed using a cotton pellet. When there was no change in gel color, the cavity was considered caries free. The cavity was then filled with high viscosity glass ionomer cement (GIC) in an encapsulated form (Riva Self-Cure, SDI Limited, Bayswater, VIC, Australia). A mechanical mixer was used to mix the capsule for 10 seconds, the capsule was placed into the applicator to apply the GIC into the cavity. For occluso-proximal cavities, a matrix strip with a wooden wedge was used to provide the appropriate contour of the restoration. A gloved finger was used to apply pressure on the GIC for one minute and occlusion was checked and excess material was removed
Trial: NCT04573608
Drug: Atraumatic Restorative Treatment
RxNorm normalized name: DRESSING,RESTORE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The tooth was cleaned with a wet cotton pellet to remove debris and plaque. Caries was removed using sharp spoon excavators (Darby-Perry #220/221, #17 DE, Hu-Friedy, Chicago, USA), followed by cleaning the cavity using a small wet cotton pellet and finally dried with a dry cotton pellet. The cavity was considered caries-free when a leather-hard texture was reached and the excavator did not stick anymore. GIC was used to restore the cavity using the same technique described for the other group.
Trial: NCT00106522
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10-25mg weekly
Trial: NCT00106522
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv every 4 weeks
Trial: NCT04561752
Drug: ZN-c5
RxNorm normalized name: dipentaerythrityl hexa C5-10 acid esters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ZN-c5 is the study drug.
Trial: NCT02908620
Drug: One spray CTY-5339-CB
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metered spray bottle with ≈200 uL total spray volume. Contains the active ingredient: 14.0% Benzocaine (USP = 28 mg). Administered in a single anesthetic spray.
Trial: NCT02742766
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This intervention is available as white oral tablet. The formulation will be used as a matching placebo for GSK3008356 during the study.
Trial: NCT00279266
Drug: Thiamine
RxNorm normalized name: Thiamine
DrugBank: Thiamine (DB00152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01906346
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cocaine will be made available for self-administration during experimental sessions.
Trial: NCT02808013
Drug: NDS-446
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02808013
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01077245
Drug: Placebo Fine Granules (without CBM588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Fine Granules (without CBM588)
Trial: NCT01007149
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was supplied in vials with solution for subcutaneous injection.
Trial: NCT00618813
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00618813
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01521585
Drug: SEN0014196
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg oral once daily tablet
Trial: NCT01521585
Drug: SEN0014196
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg oral once daily tablet
Trial: NCT02785978
Drug: Levodopa acute challenge
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Inclusion visit (simultaneous video + ActiMyo recording):~Levodopa acute challenge and 2 hours of recording and medical monitoring
Trial: NCT01913340
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo: NS IV x 5 doses
Trial: NCT01031979
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01706588
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One single diclofenac injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.
Trial: NCT01332253
Drug: Intravenous ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive a single 10mg/kg dose of intravenous ibuprofen diluted in normal saline at the induction of anesthesia.
Trial: NCT04566601
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet
Trial: NCT00362752
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 400 mg po bid
Trial: NCT02942056
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03568162
Drug: ISB 830 - Part 1 Group 1
RxNorm normalized name: meningococcal group B vaccine 0.1 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection (SC) every 2 weeks
Trial: NCT03568162
Drug: ISB 830 - Part 1 Group 2
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection (SC) every 2 weeks
Trial: NCT03568162
Drug: ISB 830 - Part 1 Group 3
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection (SC) every 2 weeks
Trial: NCT03568162
Drug: ISB 830 - Part 2 Group 5
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection (SC) every 2 weeks
Trial: NCT03568162
Drug: Placebo - Part 2 Group 6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection (SC) every 2 weeks
Trial: NCT01115673
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen Caplet - single dose
Trial: NCT01115673
Drug: Placebo Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg Caplet - single dose
Trial: NCT05257291
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Supplementation with 1 mg/day of melatonin for 1 year
Trial: NCT02227667
Drug: MEDI4736
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be seen the day of administration of MEDI4736. A medical history, with particular reference to toxicities, including medication review, and physical examination will be conducted at each treatment visit.
Trial: NCT01593592
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: clarithromycin 500mg b.i.d for 2 weeks
Trial: NCT00389493
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules will be identical in appearance to those of risperidone.